BofA analyst Jason Zemansky raised the firm’s price target on Cytokinetics (CYTK) to $63 from $62 and keeps a Neutral rating on the shares. The Q3 report and call were “uneventful” and unlikely to impact the thesis much, says the analyst, who cites adjusted operating expense projections, offset by the change in net cash, for the firm’s price target increase.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics’ Market Uncertainty and Competitive Pressures Lead to Hold Rating
- Cytokinetics’ Q3 2025: Progress in Cardiac Therapies
- Cytokinetics reports Q3 EPS ($2.55), consensus ($1.57)
- Cytokinetics price target raised to $70 from $55 at JPMorgan
- CYTK Earnings Report this Week: Is It a Buy, Ahead of Earnings?